Studies have shown that in HCC, ACE2 could serve as a protective factor and its expression was reduced in HCC patients [18–20], and also might improve the survival of patients without vascular invasion[18]; however, some limitations could be seen in these reports, such as small sample size and a lack of validation with in-house clinical samples. The gene discussed is ACE2; the disease is hepatocellular carcinoma.